Status:
COMPLETED
A Study to Evaluate the Effects of Itraconazole on MK-1708 in Healthy Participants (MK-1708-003)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Alzheimer's Disease
Eligibility:
All Genders
18-50 years
Phase:
PHASE1
Brief Summary
The goal of the study is to see what happens to levels of MK-1708 a person's body over time. Researchers will compare what happens to MK-1708 in the body when it is given with or without a medicine ca...
Eligibility Criteria
Inclusion
- The key inclusion criteria include but are not limited to the following:
- Is in good health before randomization
- Has a body mass index (BMI) ≥18.5 and ≤32 kg/m\^2, inclusive
Exclusion
- The key exclusion criteria include but are not limited to the following:
- Has a history of clinically significant endocrine, gastrointestinal (GI), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases
- Has a history of cancer
Key Trial Info
Start Date :
October 3 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 10 2024
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT06586606
Start Date
October 3 2024
End Date
December 10 2024
Last Update
December 18 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
QPS-MRA, LLC ( Site 0001)
South Miami, Florida, United States, 33143